# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserv...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Oppenheimer analyst Leland Gershell reiterates Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $7 to $5.
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
Raymond James analyst Gary Nachman initiates coverage on Veru (NASDAQ:VERU) with a Outperform rating and announces Price Tar...